Core Viewpoint - The company, Penghui Energy, is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international competitiveness [1] Group 1: Company Strategy - The company aims to deepen its global strategic layout and improve its comprehensive competitiveness in international markets [1] - The issuance of H-shares is part of the company's efforts to create an international capital operation platform and enhance its overseas financing capabilities [1] Group 2: Listing Details - The company is currently in discussions with relevant intermediaries regarding the specific progress of the H-share issuance and listing [1] - The details of the H-share issuance and listing have not yet been finalized [1] - The H-share issuance and listing will not result in changes to the company's controlling shareholder or actual controller [1]

Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. (津药药业) announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable Methylprednisolone Acetate, allowing production and sales in the Panamanian market [1] Group 1 - The drug Methylprednisolone Acetate is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases, tumors, and shock [1] - The registration application was submitted in 2024, and the certificate was received in November 2025 [1] - According to IQVIA data, the global market sales for Methylprednisolone injectable products were $526 million in 2023 and are projected to be $521 million in 2024 [1] Group 2 - The registration of Methylprednisolone Acetate in Panama presents new opportunities for the company's formulation business and further supports its international strategic layout [1]

Core Viewpoint - The company, Olin Bio, is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [2] Group 1: Company Strategy - The company aims to deepen its international strategic layout and increase its global recognition and influence [2] - The initiative is part of a broader effort to strengthen the company's overall competitive capabilities [2] Group 2: Listing Process - Currently, the company is in discussions with relevant intermediaries regarding the H-share listing [2] - Specific details about the H-share listing are yet to be determined [2] - The listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]

Group 1 - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and influence [1] - This initiative is part of the company's strategy to deepen its internationalization and optimize its capital structure [1] - The goal is to strengthen the company's overall competitiveness in the market [1]